Tackle small molecule drug discovery screening challenges with Dianthus

A big hurdle in small molecule drug discovery screening is confidently identifying positive hits in a timely manner. Screening fragment libraries is challenging with current methodologies that are either time-consuming or lack detection sensitivity. Dianthus NT.23PicoDuo utilizes a biophysical detection method for fast, precise and confident hit identification, target validation and lead optimization. An example of single-dose and affinity screening against histone methylase G9a, known to be associated with cancer onset, will be discussed.

Previous Video
Measuring stability to more effectively select therapeutic antibody candidates
Measuring stability to more effectively select therapeutic antibody candidates

This therapeutic antibody drug development webinar discusses the idea of limiting the substantial investmen...

Up next
Overcome challenges in vaccine development with deeper antigen stability characterization
Overcome challenges in vaccine development with deeper antigen stability characterization

Vaccines are biological products derived from living organisms that provide an immune response to pathogen...